Omega-3 PUFAs: Do They Really Work for the Treatment of Dementia?
BACKGROUND AND PURPOSE:
Omega-3 polyunsaturated fatty acids (omega-3 PUFAs) from fish and plants have been posited as treatment for dementia
Burckhardt et. al. (Cochrane Review, 2017) sought to test this hypothesis by assessing the efficacy and safety of omega-3 polyunsaturated fatty acid (PUFA) supplementation for the treatment of people with dementia
Searched in multiple databases and contacted manufacturers of omega-3 supplements, scanning reference lists of landmark papers and included articles
Selection criteria included studies involving Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, Parkinson’s disease dementia or frontotemporal dementia
There were 3 randomized controlled trials (RCTs), totaling 632 participants with mild to moderate Alzheimer’s disease followed over 6, 12, 18 months
The researchers did not find studies on other types of dementia
Primary outcome measures were:
Changes in global and specific cognitive function
Dementia severity and adverse effects
Authors also received unpublished data from the trial authors and collected adverse effects information from published articles
Meta-analyses were conducted for available outcome measures at 6 months
The study referenced a number of assessment scales which include but are not limited to the Alzheimer’s Disease Assessment Scale, Mini-Mental State Examination, and clinical Dementia Rating- Sum Boxes
The researchers found at 6 months
No evidence of benefit from omega-3 PUFAs on cognitive function
No effect of treatment on severity of dementia or quality of life
No difference in mental health
No difference in adverse events
1 small study showed a benefit for omega-3 PUFAs in instrumental activities of daily living after 12 months of treatment
No evidence for the efficacy of omega-3 PUFA supplements in the treatment of mild to moderate Alzheimer’s disease
Adverse effects of omega-3 PUFA are low, but a final statement on tolerability cannot be made
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan